



Novartis Pharma S.A.E
Novartis Egypt Communications
P.O.Box 11511 Cairo
Egypt

<http://www.novartis.com>

Novartis Pharma S.A.E confirms all company products in Egypt unaffected by valsartan recall

Cairo, July 31, 2018 – Novartis Pharma S.A.E (Novartis Pharma) confirms that none of its products in Egypt are affected by the decision to recall certain products containing valsartan

All Novartis Pharma products containing Valsartan Active Ingredient (API) are not affected by the recently identified impurity, N-Nitrosodimethylamine (NDMA) that was found in Valsartan API manufactured by a company in China. This Chinese manufacturing site is not a regulatory approved manufacturer of Valsartan API for any of Novartis Pharma products and is not used to manufacture neither commercial nor clinical batches of its medications. Novartis Pharma manufactures Valsartan API in its own manufacturing sites and does not rely on any external manufacturers to produce Valsartan API.

Novartis places the highest priority on patients' health and wellbeing, and ensuring access to our treatments. It is important for us to reassure patients and caregivers in Egypt that all our products in this market are safe and effective.

Disclaimer

This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures; our ability to obtain or

maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political and economic conditions; safety, quality or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. In 2017, the Group achieved net sales of USD 49.1 billion, while R&D throughout the Group amounted to approximately USD 9.0 billion. Novartis Group companies employ approximately 124,000 full-time-equivalent associates. Novartis products are sold in approximately 155 countries around the world. For more information, please visit <http://www.novartis.com>.

Novartis is on Twitter. Sign up to follow @Novartis at <http://twitter.com/novartis>
For Novartis multimedia content, please visit www.novartis.com/news/media-library
For questions about the site or required registration, please contact media.relations@novartis.com

###

Novartis Media Relations

Reem ElAdl

Egypt Corporate Head Communications and Advocacy
Telephone: +20 2 22861130
Mobile: +20 100 1879099
reem.eladl@novartis.com